Merck's Oral Cholesterol-Lowering Drug Lipfendra Approved by U.S. FDA
Taylor Wilson
The FDA has approved Merck's Lipfendra, the world's first oral PCSK9 inhibitor tablet — cutting LDL cholesterol by up to 60% in six months and giving Merck a critical new growth engine as its blockbuster Keytruda nears patent expiry.
What problem does this drug actually solve?
PCSK9 inhibitors — a class of drugs that sharply reduce "bad" cholesterol — have existed for years, but only as injections. Lipfendra is the first oral tablet in this class.
This means → patients go from a shot every few weeks to one pill a day, a far lower barrier to treatment.
Clinical data: once-daily oral dosing cut LDL (low-density lipoprotein, the "bad" cholesterol) by up to 60% over six months, and it can be combined with statins.
How much does it cost — and what will patients actually pay?
Lipfendra is listed at $10.50 per day, or $315 for a 30-day supply.
Merck says insured patients will pay well below list price, though the exact copay is not yet disclosed.
The company also plans to offer discounted pricing through the U.S. government site TrumpRx.gov; the discount level has not been announced.
Whose market is it taking?
The current leader in the class is Amgen's injectable Repatha, with annual sales of roughly $3 billion — but uptake was slow early on due to high cost and injection burden.
Another competitor is Novartis's Leqvio, an RNA-based drug injected twice a year.
In plain terms = Lipfendra's core selling point is not "stronger" but "easier" — swapping a needle for a pill to expand the total patient pool for PCSK9 therapy.
What does this mean for Merck itself?
Analysts project Lipfendra's peak annual sales at over $5 billion.
This means → if that estimate holds, Lipfendra would become Merck's second-largest product after Keytruda.
The strategic context: Merck's star oncology drug Keytruda faces generic competition within the next few years. Lipfendra is the key new growth engine meant to fill that potential revenue gap.
What is still unresolved?
Merck is running an additional study to determine whether Lipfendra's cholesterol reduction also lowers the actual rate of heart attacks and strokes.
In plain terms = so far, the drug has proven it brings the numbers down — it has not yet proven people get sick less often as a result. The latter is the critical validation point for long-term market value.
This reflects a broader industry question: lowering a biomarker ≠ lowering risk. Until endpoint data arrive, the $5 billion peak-sales estimate still carries uncertainty.
Content is for reference only, not financial advice.